This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Click here for Vydura® (rimegepant) Prescribing Information for Great Britain and Northern Ireland. Adverse event reporting information can be found at the bottom of the page.
The possibility of acute treatment of migraine or preventative treatment of migraine in adults with VYDURA.2
VYDURA is indicated for:2
The possibility to treat or prevent migraine with VYDURA2
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim…
With VYDURA you can treat acute migraine or use for the preventative treatment of episodic migraine based on the criteria your patient meets1,2
To learn more about Vydura and it's impact on Calcitonin Gene-Related Peptide Receptors, visit the Mechanism of Action page below
Acute treatment of migraine with or without aura in adults.2
Learn about VYDURA’s recommended dosing schedule, advice for patients and coadministration of medicines
Discover the efficacy and safety profile for VYDURA
To receive tailored marketing information from Pfizer by email, sign up here.
Learn more about migraines including how to diagnose, the imact on patients and society, patient views, pathopysiological and complete case-based learning.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024